# US 2010/0168032 A1 · Smart Pro-Drugs of Serine Protease Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168032 A1
- Document ID: US20100168032A1
- Status: Published application
- Kind: A1
- Application number: 12/568,210
- Filed: 2009-09-28
- Published: 2010-07-01
- Earliest claimed: 2002-04-30
- Assignees: Trustees of Tufts College
- Inventors: William W. Bachovchin
- Web page: https://patentgrep.com/patent/US20100168032A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/10: Laxatives
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07F 5/025: {Boronic and borinic acid compounds}
- C07K 5/06052: {Val-amino acid}
- C07K 5/06078: {and aromatic or cycloaliphatic}
- C07K 5/06191: {containing heteroatoms different from O, S, or N}
- C07K 5/0817: {the first amino acid being Arg}
- C07K 5/0827: {containing heteroatoms different from O, S, or N}
- C07K 5/1008: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- C07K 5/101: {the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu}
- C07K 5/1013: {the side chain containing O or S as heteroatoms, e.g. Cys, Ser}
- C07K 5/1016: {and aromatic or cycloaliphatic}
- C07K 5/1027: {containing heteroatoms different from O, S, or N}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to prodrugs of protease inhibitors, such as inhibitors of the proteosome, DPP IV, FAPα and the like. These “pro-inhibitors” are activated, i.e., cleaved, by an “activated protease” to release an active inhibitor moiety in proximity to a “target protease”. The identity of activating protease and target protease can be the same (such as pro-inhibitors being referred to as “Target-Activated Smart Protease Inhibitors” or “TASPI”) or different (e.g., “Target-Directed Smart Protease Inhibitors” or “TDSPI”). After activation of the pro-inhibitor, the active inhibitor moiety can self-inactivate by, e.g., intramolecular-cyclization or cis-trans isomerization.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A prodrug represented by formula (I) or a solvate, pharmaceutically functional derivative or pharmaceutically acceptable salt thereof:
A-G (I)
wherein
A represents a peptidyl moiety, 2-10 amino acid residues in length, that is a substrate for an activating protease which is associated with tumors; A and G are covalently linked by a bond that is cleaved by the activating protease; and
G represents a dipeptidyl proteosome inhibitor moiety that, when released from the prodrug by cleavage by the activating protease, inhibits the proteolytic activity of a proteosome with a Ki of 100 nM or less,
wherein, the dipeptidyl proteosome inhibitor moiety G, when cleaved from A by the activating protease, undergoes reversible cyclization-dependent inactivation over time.

### Claim 30 (depends on 29)

The prodrug of claim 29, wherein A is a dipeptidyl or tripeptidyl moiety.

### Claim 31 (depends on 29)

The prodrug of claim 29, wherein at least one residue of A is a non-naturally occurring amino acid analog.

### Claim 32 (depends on 29)

The prodrug of claim 29, wherein at least one residue of A is a D-amino acid.

### Claim 33 (depends on 29)

The prodrug of claim 29, wherein the amino terminus of A is blocked with an amino-terminal protecting group.

### Claim 34 (depends on 33)

The prodrug of claim 33, wherein the amino-terminal protecting group is an acyl group.

### Claim 35 (depends on 34)

The prodrug of claim 34, wherein the acyl group is selected from the group consisting of formyl, dansyl, acetyl, benzoyl, trifluoroacetyl, succinyl and methoxysuccinyl.

### Claim 36 (depends on 29)

The prodrug of claim 29, wherein the dipeptidyl proteosome inhibitor moiety G is represented by formula (II):
Xaa1-Xaa2-W (II)
wherein
Xaa1 and Xaa2 each independently represent an amino acid residue;
W represents —CN, —CH═NR5,
R5 represents H, an alkyl, an alkenyl, an alkynyl, —C(X1)(X2)X3, —(CH2)m-R6, —(CH2)n-OH, —(CH2)n-O-alkyl, —(CH2)n-O-alkenyl, —(CH2)n-O-alkynyl, —(CH2)n-O—(CH2)m-R6, —(CH2)n-SH, —(CH2)n-S-alkyl, —(CH2)n-S-alkenyl, —(CH2)n-S-alkynyl, —(CH2)n-S—(CH2)m—R6, —C(O)C(O)NH2, —C(O)C(O)OR7;
R6 represents, independently for each occurrence, a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle;
R7 represents, independently for each occurrence, hydrogen, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle;
Y1 and Y2 can independently or together be OH, or a group capable of being hydrolyzed to a hydroxyl group, including cyclic derivatives where Y1 and Y2 are connected via a ring having from 5 to 8 atoms in the ring structure;
R50 represents O or S;
R51 represents N3, SH2, NH2, NO2 or —OR7;
R52 represents hydrogen, a lower alkyl, an amine, —OR7, or a pharmaceutically acceptable salt, or R51 and R52 taken together with the phosphorous atom to which they are attached complete a heterocyclic ring having from 5 to 8 atoms in the ring structure;
X1 represents a halogen;
X2 and X3 each represent a hydrogen or a halogen;
m is zero or an integer in the range of 1 to 8; and n is an integer in the range of 1 to 8.

### Claim 37 (depends on 36)

The prodrug of claim 36, wherein W is
and Y1 and Y2 are OH.

### Claim 38 (depends on 36)

The prodrug of claim 36, wherein Xaa1 or Xaa2 is a non-naturally occurring amino acid analog.

### Claim 39 (depends on 29)

The prodrug of claim 29, wherein the activating protease is Fibroblast Activating Protein (FAP), Prostate Specific Antigen (PSA), Dipeptidylpeptidase IV (DPIV), matriptase or falcipain.

### Claim 40 (depends on 39)

The prodrug of claim 39, wherein the activating protease is Fibroblast Activating Protein (FAP).

### Claim 41 (depends on 29)

The prodrug of claim 29, wherein the reversible cyclization-dependent inactivation comprises the dipeptidyl proteosome inhibitor moiety G undergoing inter-conversion between linear and cyclic forms, wherein the cyclic form has a Ki for inhibiting the proteosome at least 2 times greater than the linear form.

### Claim 42 (depends on 29)

The prodrug claim 29, wherein the cyclic form has a Ki at least 10 times the Ki of the linear form.

### Claim 43 (depends on 29)

The prodrug of claim 29, wherein the cyclic form has a Ki at least 100 times the Ki of the linear form.

### Claim 44 (depends on 29)

The prodrug of claim 29, wherein the prodrug has a therapeutic index at least two times greater than the therapeutic index for the dipeptidyl proteosome inhibitor moiety G when administered alone.

### Claim 45 (depends on 29)

A pharmaceutical composition, comprising a pharmaceutically acceptable carrier; and a prodrug of claim 29, or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 29)

A packaged pharmaceutical, comprising one or more prodrugs of claim 29 formulated in a pharmaceutically acceptable excipient, in association with instructions (written and/or pictorial) describing the recommended dosage and/or administration of the formulation to a patient.
